Maik Hauschild

2.4k total citations
24 papers, 593 citations indexed

About

Maik Hauschild is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Maik Hauschild has authored 24 papers receiving a total of 593 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Cancer Research, 14 papers in Oncology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Maik Hauschild's work include Breast Cancer Treatment Studies (15 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Treatment and Pharmacology (9 papers). Maik Hauschild is often cited by papers focused on Breast Cancer Treatment Studies (15 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Treatment and Pharmacology (9 papers). Maik Hauschild collaborates with scholars based in Germany, Switzerland and Austria. Maik Hauschild's co-authors include Sibylle Loibl, Jens Huober, Hans Tesch, Christoph Thomssen, Carsten Denkert, Jens‐Uwe Blohmer, Dirk M. Zahm, F Khandan, B. Högel and Erich Weiß and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Maik Hauschild

24 papers receiving 578 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maik Hauschild Germany	11	415	402	161	111	94	24	593
G. Raab Germany	7	483 1.2×	487 1.2×	178 1.1×	81 0.7×	67 0.7×	19	650
Debbie Frye United States	8	373 0.9×	396 1.0×	126 0.8×	101 0.9×	44 0.5×	13	556
Maheshwari Ramineni United States	7	338 0.8×	308 0.8×	132 0.8×	123 1.1×	84 0.9×	16	539
Günther Raab Germany	8	465 1.1×	394 1.0×	210 1.3×	62 0.6×	56 0.6×	10	605
S. Kahlert Germany	6	299 0.7×	445 1.1×	93 0.6×	138 1.2×	132 1.4×	12	539
Angela Sciandivasci Italy	11	286 0.7×	425 1.1×	63 0.4×	191 1.7×	85 0.9×	23	593
Emma J. Groen Netherlands	9	205 0.5×	243 0.6×	212 1.3×	65 0.6×	49 0.5×	15	485
Helen Trihia Greece	10	262 0.6×	273 0.7×	149 0.9×	65 0.6×	31 0.3×	24	465
R. S. Gelman United States	10	306 0.7×	363 0.9×	139 0.9×	98 0.9×	36 0.4×	17	521
Maggie Wilcox United Kingdom	6	304 0.7×	340 0.8×	83 0.5×	168 1.5×	42 0.4×	9	512

Countries citing papers authored by Maik Hauschild

Since Specialization

Citations

This map shows the geographic impact of Maik Hauschild's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maik Hauschild with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maik Hauschild more than expected).

Fields of papers citing papers by Maik Hauschild

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maik Hauschild. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maik Hauschild. The network helps show where Maik Hauschild may publish in the future.

Co-authorship network of co-authors of Maik Hauschild

This figure shows the co-authorship network connecting the top 25 collaborators of Maik Hauschild. A scholar is included among the top collaborators of Maik Hauschild based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maik Hauschild. Maik Hauschild is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Kolberg, Hans‐Christian, Thorsten Kühn, Ingo Bauerfeind, et al.. (2020). Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases – a transSENTINA Analysis. Geburtshilfe und Frauenheilkunde. 80(12). 1229–1236. 5 indexed citations

2.

Kolberg, Hans‐Christian, Thorsten Kühn, Ingo Bauerfeind, et al.. (2020). Correction: Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases – a transSENTINA Analysis. Geburtshilfe und Frauenheilkunde. 80(12). e290–e290. 3 indexed citations

3.

Untch, Michael, Gϋnter von Minckwitz, Bernd Gerber, et al.. (2018). Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). Journal of Clinical Oncology. 36(13). 1308–1316. 40 indexed citations

4.

Schwentner, Lukas, G Helms, Valentina Nekljudova, et al.. (2016). Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy – Results from the multi-center SENTINA trial. The Breast. 31. 202–207. 49 indexed citations

5.

Untch, Michael, Gϋnter von Minckwitz, B. Gerber, et al.. (2015). 1801 Neoadjuvant chemotherapy with trastuzumab or lapatinib: Survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44). European Journal of Cancer. 51. S264–S264. 1 indexed citations

6.

Gerber, Bernd, Gϋnter von Minckwitz, Holger Eidtmann, et al.. (2014). Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44). Annals of Surgical Oncology. 21(8). 2517–2524. 16 indexed citations

7.

Cortés, Javier, Sandra M. Swain, Iveta Kudaba, et al.. (2013). Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel. Anti-Cancer Drugs. 24(10). 1084–1092. 19 indexed citations

8.

Gerber, B., Sibylle Loibl, Holger Eidtmann, et al.. (2013). Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Annals of Oncology. 24(12). 2978–2984. 105 indexed citations

9.

Fasching, PA, Maik Hauschild, Sherko Kümmel, et al.. (2012). Abstract PD07-02: Anticancer activity of letrozole plus zoledronic acid as neoadjuvant therapy for postmenopausal patients with breast cancer: FEMZONE trial results. Cancer Research. 72(24_Supplement). PD07–2. 2 indexed citations

10.

Guo, Xinrong, Sibylle Loibl, Michael Untch, et al.. (2011). Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy. Breast Care. 6(4). 279–283. 11 indexed citations

11.

Llombart‐Cussac, Antonio, Maik Hauschild, M. Venturini, et al.. (2011). P3-14-13: A Prospective Open-Label Randomized Phase II Neoadjuvant Study of Non-Pegylated Liposomal Doxorubicin (MYOCET®) Plus Cyclophosphamide and Trastuzumab Versus Conventional Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in HER2−Positive Breast Cancer Patients.. Cancer Research. 71(24_Supplement). P3–14. 1 indexed citations

12.

Witzel, Isabell, Sibylle Loibl, G von Minckwitz, et al.. (2010). Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Research and Treatment. 123(2). 437–445. 37 indexed citations

13.

Huober, Jens, Carsten Denkert, Hans Tesch, et al.. (2010). Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Research and Treatment. 124(1). 133–140. 220 indexed citations

14.

Woelber, Linn, Karin Hellner, Friederike Gieseking, et al.. (2008). Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. Archives of Gynecology and Obstetrics. 279(6). 803–807. 4 indexed citations

15.

Kümmel, Sherko, Anke Thomas, Maik Hauschild, et al.. (2006). Postoperative therapy modalities for cervical carcinoma.. PubMed. 26(2C). 1707–13. 6 indexed citations

16.

Guski, Hans, Lilli Geworski, D. L. Munz, et al.. (2004). Subareolar injection of technetium-99m nanocolloid yields reliable data on the axillary lymph node tumour status in breast cancer patients with previous manipulations on the primary tumour: a prospective study of 117 patients. European Journal of Nuclear Medicine and Molecular Imaging. 31(5). 671–675. 14 indexed citations

17.

Blohmer, Jens‐Uwe, Maik Hauschild, J. Hilfrich, et al.. (2004). Safety and efficacy of first-line epirubicin–docetaxel (ED) versus epirubicin–cyclophosphamide (EC): A multicenter randomized phase III trial in metastatic breast cancer (MBC). Journal of Clinical Oncology. 22(14_suppl). 627–627. 8 indexed citations

18.

Blohmer, Jens‐Uwe, Maik Hauschild, J. Hilfrich, et al.. (2004). Safety and efficacy of first-line epirubicin–docetaxel (ED) versus epirubicin–cyclophosphamide (EC): A multicenter randomized phase III trial in metastatic breast cancer (MBC). Journal of Clinical Oncology. 22(14_suppl). 627–627. 2 indexed citations

19.

Hauschild, Maik, A. Thomas, Sofiane Maza, et al.. (2004). Sentinel node biopsy in breast cancer after neoadjuvant therapy. Journal of Clinical Oncology. 22(14_suppl). 691–691. 3 indexed citations

20.

Hauschild, Maik, et al.. (1994). Untersuchungen zur Meßgenauigkeit kommerzieller Atemfunktionsmeßplätze und Beatmungsmonitore für Neugeborene*. Klinische Pädiatrie. 206(3). 167–174. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact